Analytical Data
-
Gene name
IL27A
- Application
-
Alternative Names
IL27A；IL27A；IL30；Interleukin-27 subunit alpha
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8NEV9
-
Expression Region
29-243aa
-
AA Sequence
FP RPPGRPQLSL QELRREFTVS LHLARKLLSE VRGQAHRFAE SHLPGVNLYL LPLGEQLPDV SLTFQAWRRL SDPERLCFIS TTLQPFHALL GGLGTQGRWT NMERMQLWAM RLDLRDLQRH LRFQVLAAGF NLPEEEEEEE EEEEEERKGL LPGALGSALQ GPAQVSWPQL LSTYRLLHSL ELVLSRAVRE LLLLSKAGHS VWPLGFPTLS PQP
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-27 (IL-27) is a cytokine belonging to the interleukin-6 (IL-6) and IL-12 family, which plays a pivotal role in regulating immune responses. It is primarily produced by dendritic cells and macrophages and acts on various immune cells, including T cells, to promote Th1 differentiation and inhibit Th2 responses. The recombinant protein of IL-27, known as IL27A, has garnered significant interest in immunology and therapeutic research due to its potential applications in treating autoimmune diseases, infections, and cancers. IL27A exhibits both pro-inflammatory and anti-inflammatory properties, which complicate its role in disease but highlights its therapeutic promise. Studies have shown that IL27A can enhance the activity of cytotoxic T lymphocytes, thereby boosting anti-tumor immunity, while also modulating regulatory T cells to reduce excessive inflammatory responses. Furthermore, research into IL27A is exploring its mechanisms of action, signaling pathways, and interactions with other cytokines, which could lead to novel therapeutic strategies that leverage its dual roles in the immune system. Additionally, understanding the structural and functional characteristics of recombinant IL27A can facilitate the development of more effective cytokine-based therapies, underscoring the importance of continued research in this area. As the understanding of IL27A advances, it holds the potential to inform new treatment modalities for various immune-related conditions, making it a critical focus for both basic and translational research in immunology.
